NOV 08, 2017 6:00 AM PST

How to Monitor Heparin Therapy: Still a Controversy

Speaker
  • Clinical Research Scientist, 59th CRD
    Biography
      David L. McGlasson, MS. MLS(ASCP)cm was a staff researcher at the 59th Clinical Research Division at Lackland JBSA in San Antonio, TX until his retirement.. He has published 166 abstracts, 76 manuscripts, 9 book chapters, three patents and one book. Mr. McGlasson has also presented more than 200 lectures at local, state, national and international levels. He is the 9 time winner of the American Clinical Laboratory Science Award for scientific research and has received the Kendall-Sherwood Award, the Bio-Rad award for scientific achievement in Hematology. He also has won numerous poster competitions at many meetings. To include the Society of Armed Forces Laboratory Science, International Society of Thrombosis and Hemostasis and American Society of Clinical Laboratory Science. He currently is a consulatant in the area of Hemostasis and Thrombosis.

    Abstract

    Monitoring unfractionated heparin (UFH) using the activated partial thromboplastin time (APTT) or the anti-factor Xa (anti-Xa) chromogenic assay still seems to be a controversy.  Is the anti-Xa less affected by pre-analytical variables in monitoring subjects on UFH and the low molecular weight heparins (LMWH)?  Which assay is more accurate in monitoring heparin to achieve therapeutic levels, cost effective in time spent monitoring patients, use of blood products, time in the hospital, and overall cost which may include laboratory testing time.  The APTT still is the most commonly used assay to monitor UFH therapy but cannot be used to monitor the LMWHs.  Previous studies have cited interference in monitoring UFH with the  APTT from oral anticoagulants, oral contraceptives, lupus anticoagulants, factor deficiencies, elevated acute phase reactants (fibrinogen, FVIII), low anti-thrombin, the APTT reagent sensitivity and instrumentation.  The anti-Xa assay may be affected by hyperbilirubinemia, hyperlipidemia (can be cleared by ultracentrifugation) and decreased anti-thrombin levels (assay dependent). The anti-Xa assay can be used to monitor all heparin analogues and direct oral anticoagulants (DOACs).  This presentation will discuss the pros and cons of both methods and which may be most effective in patient care.


    Show Resources
    You May Also Like
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    AUG 18, 2020 10:00 AM PDT
    C.E. CREDITS
    AUG 18, 2020 10:00 AM PDT
    DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    DEC 09, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 09, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 09, 2020 TIME: 09:00am PDT Hematopoietic stem cells (HSCs) ensure homeostasis of blood throughout life. In this webinar, we share insights into the smart and easy isolation, c...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees
    • See more